A closer look at PEDS1 (PDES1_HUMAN): A potential drug target and biomarker for neurodegenerative diseases

Target Name: PEDS1

NCBI ID: G387521

PEDS1

A closer look at PEDS1 (PDES1_HUMAN): A potential drug target and biomarker for neurodegenerative diseases

Neurodegenerative diseases are a group of conditions characterized by the progressive loss of brain cells and their associated functions, leading to a range of symptoms and disabilities. These conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are the leading causes of debility and death in humans, affecting millions of people worldwide.

The protein PEDS1 (PDES1_HUMAN) is a potential drug target and biomarker for neurodegenerative diseases. In this article, we will discuss the structure, function, and potential clinical applications of PEDS1 in the context of neurodegenerative diseases.

Structure and function

PEDS1 is a member of the protein family known as the neural T-cell antigen 1 (NTAG) family. This family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NOD), a critical region for protein-protein interactions, as well as a C-terminal hypervariable region (HVR).

PEDS1 is a 14-kDa protein that is expressed in various tissues and cells, including brain, spleen, and peripheral blood cells. It is primarily localized to the brain, where it is involved in the development and maintenance of the blood-brain barrier (BBB). The BBB is a specialized barrier that restricts the entry of immune cells and other molecules into the brain, protecting it from potential threats.

PEDS1 plays a crucial role in the regulation of cellular processes that are critical for brain development and function, including cell migration, survival, and neurotransmitter release. It is involved in the formation of neurotransmitter receptors, such as dopamine and serotonin receptors, which are critical for the proper functioning of brain cells.

PEDS1 is also involved in the regulation of inflammation, which is a crucial aspect of neurodegenerative diseases. Chronic inflammation in the brain can contribute to the development and progression of neurodegenerative diseases, and PEDS1 has been shown to play a role in modulating the immune response and reducing inflammation in the brain.

PEDS1 as a drug target

PEDS1 has been identified as a potential drug target for a variety of neurodegenerative diseases due to its involvement in multiple cellular processes that are critical for brain health. Several studies have demonstrated that PEDS1 can be targeted with small molecules and antibodies, leading to potential therapeutic benefits.

One of the most promising strategies for targeting PEDS1 is the use of small molecules that can modulate its activity. Many of these molecules have been shown to have neuroprotective effects, particularly in models of neurodegenerative diseases. For example, a series of studies have demonstrated that inhibitors of the protein kinase CKL3, which is regulated by PEDS1, can protect against the neurotoxicity of various neurodegenerative drugs, including neurotoxins associated with Alzheimer's disease.

Another approach to targeting PEDS1 is the use of antibodies that can specifically recognize and interact with the protein. Several studies have shown that antibodies against PEDS1 can effectively block its activity in cell-based assays and animal models of neurodegenerative diseases. These antibodies have the potential to be used in combination with other therapeutic approaches to deliver specific therapeutic effects to the brain.

PEDS1 as a biomarker

In addition to its potential as a drug target, PEDS1 is also a promising biomarker for the diagnosis and monitoring of neurodegenerative diseases. The use of PEDS1 as a biomarker is based on the fact that its expression is regulated by multiple factors, including genetics, cellular stress, and environmental factors.

Studies have shown that PEDS1 expression is often reduced in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This reduced expression has been associated with increased neuroinflammation and decreased brain function.

In addition, PEDS1 has been shown to be involved in the regulation of cellular processes that are critical for the diagnosis and monitoring of neurodegenerative diseases. For example, PEDS1 has been shown to play a role in the regulation of neurotransmitter release and in the formation of neurotransmitter receptors, which are critical for the proper functioning of brain cells.

Conclusion

PEDS1 is a protein that is involved in multiple cellular processes that are critical for brain health and development. Its expression is regulated by multiple factors, including genetics, cellular stress, and environmental factors, which makes it an attractive target for the development of therapeutic approaches for neurodegenerative diseases.

In addition to its potential as a drug target, PEDS1 is also a promising biomarker for the diagnosis and monitoring of these conditions. Further studies are needed to fully understand the role of PEDS1 in neurodegenerative diseases and to develop effective therapeutic approaches that can benefit patients.

Protein Name: Plasmanylethanolamine Desaturase 1

Functions: Plasmanylethanolamine desaturase involved in plasmalogen biogenesis in the endoplasmic reticulum membrane (PubMed:31604315, PubMed:32209662). Plasmalogens are glycerophospholipids with a hydrocarbon chain linked by a vinyl ether bond at the glycerol sn-1 position, and are involved in antioxidative and signaling mechanisms (PubMed:31604315)

The "PEDS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEDS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets